{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:41Z","timestamp":1792787921921,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011912","name":"School of Medicine, Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.07.022","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T06:57:24Z","timestamp":1753945044000},"page":"838.e1-838.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0468-5885","authenticated-orcid":false,"given":"Sai Kit","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7629-7224","authenticated-orcid":false,"given":"Patrick W.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ancheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0719-2964","authenticated-orcid":false,"given":"Karyn A.","family":"Tindbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0087-6256","authenticated-orcid":false,"given":"Mandeep K.","family":"Sekhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Albittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam E.","family":"Kopmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1880-7094","authenticated-orcid":false,"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre V.","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-8288","authenticated-orcid":false,"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7532-4822","authenticated-orcid":false,"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-6591","authenticated-orcid":false,"given":"Hu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M.","family":"Leisenring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5790-4770","authenticated-orcid":false,"given":"Emily C.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2025.07.022_bib0001","first-page":"1","article-title":"CAR T-cell immunotherapy of B-cell malignancy: the story so far","volume":"8","author":"Halim","year":"2020","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.022_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.022_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2025.07.022_bib0006","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2025.07.022_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10343","key":"10.1016\/j.jtct.2025.07.022_bib0008","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2025.07.022_bib0009","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.jtct.2025.07.022_bib0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.022_bib0011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.07.022_bib0012","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2025.07.022_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jtct.2025.07.022_bib0014","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.07.022_bib0015","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.jtct.2025.07.022_bib0016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.022_bib0017","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2025.07.022_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.022_bib0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.07.022_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.46989\/001c.115932","article-title":"Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy","volume":"6","author":"Ahmed","year":"2024","journal-title":"Clin Hematol Int"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.jtct.2025.07.022_bib0022","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transplant Infect Dis"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.022_bib0023","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.jtct.2025.07.022_bib0024","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.jtct.2025.07.022_bib0025","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jtct.2025.07.022_bib0026","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.022_bib0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.022_bib0028","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymph"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0029","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12967-024-05308-2","article-title":"Rapid identification of early infections in febrile patients after CD19 target CAR-T cell therapy for B-cell malignancies","volume":"22","author":"Pu","year":"2024","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.022_bib0030","doi-asserted-by":"crossref","first-page":"ofae398","DOI":"10.1093\/ofid\/ofae398","article-title":"Chimeric antigen receptor T-cell postinfusion fever: infection profile, clinical parameters, and biomarkers trends to assist antibiotic stewardship","volume":"11","author":"Peyrony","year":"2024","journal-title":"Open Forum Infect Dis."},{"issue":"7","key":"10.1016\/j.jtct.2025.07.022_bib0031","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2025.07.022_bib0033","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.07.022_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106874","article-title":"CRO infection and the use of MRSA-active medication for prophylaxis affect the prognosis of patients with hematological malignancies after CAR-T infusion","volume":"62","author":"Yang","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.022_bib0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/432940","article-title":"Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy","volume":"41","author":"Ebbing","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"30","key":"10.1016\/j.jtct.2025.07.022_bib0036","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.022_bib0037","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jinf.2009.02.002","article-title":"Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies","volume":"58","author":"Trecarichi","year":"2009","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.022_bib0038","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.022_bib0039","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.2024025366","article-title":"Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy","volume":"145","author":"Prasad","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-019-0155-8","article-title":"Gut microbiome and CAR-T therapy","volume":"8","author":"Abid","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2025.07.022_bib0041","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1182\/blood-2021-153117","article-title":"High bacterial abundances of dorea and pediococcus in the gut microbiome linked to expansion, immune checkpoint expression and efficacy of CD19-directed CAR T-cells in patients with r\/r DLBCL","volume":"138","author":"Blumenberg","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.07.022_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.670286","article-title":"The potential role of the intestinal micromilieu and individual microbes in the immunobiology of chimeric antigen receptor T-cell therapy","volume":"12","author":"Schubert","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0043","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10408363.2013.764490","article-title":"Biomarkers of sepsis","volume":"50","author":"Faix","year":"2013","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0044","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13054-021-03862-5","article-title":"Biomarkers for sepsis: more than just fever and leukocytosis\u2014a narrative review","volume":"26","author":"Barichello","year":"2022","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.022_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4143\/crt.2011.43.3.176","article-title":"The usefulness of procalcitonin and C-reactive protein as early diagnostic markers of bacteremia in cancer patients with febrile neutropenia","volume":"43","author":"Kim","year":"2011","journal-title":"Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.022_bib0046","first-page":"2863","article-title":"Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis","volume":"23","author":"Wu","year":"2015","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2025.07.022_bib0047","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3109\/10428194.2011.597904","article-title":"Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis","volume":"52","author":"Juutilainen","year":"2011","journal-title":"Leuk Lymph"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0767-x","article-title":"Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy","volume":"7","author":"Luo","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.022_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0051","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30236-9","article-title":"Machine learning for fast identification of bacteraemia in SIRS patients treated on standard care wards: a cohort study","volume":"8","author":"Ratzinger","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.022_bib0052","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.jtct.2025.07.022_bib0053","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.07.022_bib0054","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.; 2017. https:\/\/www.meddra.org\/"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.022_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.022_bib0056","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41409-024-02278-3","article-title":"Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity","volume":"59","author":"Liang","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.022_bib0057","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti\u2013IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.022_bib0058","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1378\/chest.09-2920","article-title":"Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial","volume":"138","author":"M\u00fcller","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtct.2025.07.022_bib0059","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2019.01.015","article-title":"Gut microbiome and cancer immunotherapy","volume":"447","author":"Li","year":"2019","journal-title":"Cancer Lett"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.022_bib0060","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/cid\/ciad389","volume":"77","author":"Weber","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2025.07.022_bib0061","doi-asserted-by":"crossref","first-page":"708.e1","DOI":"10.1016\/j.jtct.2023.08.013","article-title":"Early antibiotic deescalation and discontinuation in patients with febrile neutropenia after cellular therapy: a single-center prospective unblinded randomized trial","volume":"29","author":"Ram","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.022_bib0062","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.chest.2016.08.1460","article-title":"Culture-negative severe sepsis: nationwide trends and outcomes","volume":"150","author":"Gupta","year":"2016","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.022_bib0063","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.07.022_bib0064","unstructured":"Centers for Disease Control and Prevention. Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection). 2025. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/4psc_clabscurrent.pdf"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725013351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725013351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:39:09Z","timestamp":1790825949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725013351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725013351"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}